Navigation Links
Researchers help in search for new ways to image, therapeutically target melanoma
Date:11/3/2011

TAMPA, Fla. (Nov. 3, 2011) Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy. A tool of great promise comes from the world of nanomedicine where tiny drug delivery systems are measured in the billionths of meters and are being designed to deliver targeted therapies.

Which therapies are appropriate to be loaded into nano-sized vehicles to attach to the right receptors for targeting purposes is an issue.

"Melanoma progression is associated with altered expression of cell surface proteins, including adhesion proteins and receptors," said study co-author David L. Morse, Ph.D., whose work at Moffitt includes experimental therapeutics and diagnostic imaging. "Eighty percent of malignant melanomas express high levels of the MC1R receptor, one of a family of five receptors."

Their study, published in a recent issue of the Journal of Medicinal Chemistry, tested the family of receptors, including MC1R, to find out which receptors would respond best when the right ligand was loaded into a nano-sized spherical delivery device resembling a Koosh Ball called a "micelle."

According to study co-author Robert J. Gillies, Ph.D., director of Molecular and Functional Imaging and vice chair of Radiology Research at Moffitt, MC1R has been in the past investigated as a target for selective imaging and for potential therapeutic agents and is known to play a role in skin pigmentation and hair color. The search for the right "ligand" (a substance that forms a complex with a biomolecule) for use in targeting the right receptor, is ongoing.

"The development of ligands that can be attached to micelles and/or nanoparticles to target cancer cells relative to healthy organs is a subject of great research and great potential," said Gilles.

However, failures in this effort can emerge when attachments lose affinity, when poor stability results in collapse before the nano-sized vehicle gets to the vicinity of the tumor, or when the nanoparticle size is too big to escape the body's vascular system. Each issue needs to be addressed, said Gillies.

In this study, Gilles and Morse and colleagues tested one ligand that was found to have "high affinity and selectivity" for MC1R. That ligand was subsequently modified for attachment to a polymer micelle. Noting the three hurdles to be overcome ligand affinity, nanoparticle stability and right nanoparticle size the authors concluded that their chosen ligand "remained selective after attachment" and that the increased binding affinity of the ligand to MC1R demonstrated the stability of the system.

"We are also confident that our micelles are of sufficient size to escape the vasculature, and studies in mice are underway to evaluate the selectivity and stability of this targeted micelle system," concluded Morse.

The Moffitt researchers and their colleagues also feel that this development is a step in the right direction toward more effective imaging of malignant melanoma as well as the development of better targeted therapies for individualized treatment of the disease using nano-sized drug delivery systems.


'/>"/>

Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Univesity of Notre Dame researchers form new partnership to help trauma patients
2. Ohio State researchers design a viral vector to treat a genetic form of blindness
3. Researchers reveal potential treatment for sickle cell disease
4. Senior citizens as co-researchers to improve urban planning
5. Plant researchers locate transporter used for nicotine metabolism
6. Live-action films of worm sperm help researchers track critical fertility enzymes
7. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
8. Researchers identify potential risk factors for severe altitude sickness
9. Moffitt Cancer Center researchers find more clues to causes of breast cancer
10. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
11. Medical researchers ID potential new drug target that could stop debilitating effects of MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more ... Trump expressing their support for an independent Vaccine Safety Commission. Five of the ... medical journalist, will hold a press conference at 9:00 AM Friday, March ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... -- Global intravenous (IV) iron and oral iron market is ... a CAGR of 5%. Iron drugs are ... anemia or other iron deficiencies. Oral iron supplements are recommended ... some cases, oral administrations are not capable of maintaining the ... comes into the picture. Global Intravenous (IV) Iron ...
Breaking Medicine Technology: